Navigation Links
Chemed Corporation Purchases a Second Corporate Jet - MMI Investments Demands an End to Chemed Corporate Largesse
Date:4/2/2009

The MMI Director Nominees Will Bring Much-Needed Independence and Stockholder Representation to the Chemed Board

NEW YORK, April 2 /PRNewswire/ -- MMI Investments, L.P. ("MMI") today announced that it has sent a letter to the newly-elected Chairman of Chemed Corporation ("Chemed"), George J. Walsh III, demanding that Chairman Walsh promptly dismantle Chemed's culture of corporate largesse, as embodied in Chemed's November 2008 purchase of a corporate jet for nearly $9 million.

MMI President Clay B. Lifflander stated: "This November when many of America's largest companies were being publicly excoriated for wasting stockholder capital on corporate jets, Chemed's management and board decided to double its own fleet, acquiring a second 15-seat Hawker private jet. Yet even though this purchase accounted for more than 36% of 2008 capital expenditures for the whole company, there was no mention of it on the fourth quarter conference call and no disclosure in the company's 2008 10K as to why 2008 corporate level capital expenditures were nearly 50 and 70 times 2007 and 2006 levels, respectively."

"MMI nominated a highly qualified slate of independent director candidates for the Chemed Board because of entrenchment such as this. We fear that Chemed's management and Board simply do not understand that they are merely stewards of stockholder capital -- not owners of it."

The full text of MMI's letter to Chairman Walsh follows:

    April 2, 2009

    Chairman George J. Walsh III
    Chemed Corporation
    2600 Chemed Center
    255 East Fifth Street
    Cincinnati, Ohio 45202-4726

Dear Chairman Walsh,

As a major long-term stockholder in Chemed Corporation ("Chemed"), MMI Investments, L.P. ("MMI") believes that one of your first priorities as Chemed's new Chairman should be the dismantling of Chemed's culture of corporate largesse. The most egregious example (of which we are aware) is Chemed's aircraft subsidiary, Jet Resources Inc., which expanded its fleet in November 2008, acquiring a 2001 Hawker 800XP for nearly $9 million.

We believe this expenditure is absurd in a company of Chemed's size and structure, representing 13.4% (not including the undisclosed carrying costs) of 2008 GAAP net income, over 36% of total 2008 capital expenditures and increases over Chemed's corporate level capital expenditures for 2006 and 2007 of nearly 7,000% and 5,000%, respectively. Even more troubling is that Chemed's board could justify the purchase of a $9 million Hawker 800XP when it already owns a Hawker 700, also a 15-seat aircraft. While Jet Resources Inc. does in fact offer charter services (an industry that ground to a halt well before November 2008 and that even in good times has no relevance to Chemed's two operating businesses, hospice care and plumbing/drain cleaning), it continues to do so solely with the Hawker 700 as we understand the new Hawker 800XP has not even been licensed for charter use. We note that the company's subsidiaries are all in North America, largely near major airports and managed in a decentralized fashion, and that the company's headquarters are in Cincinnati, home to a major airport and a Delta Airlines hub. An analysis of Chemed's new plane's activities since its purchase shows it reaching such highly-trafficked locations as Boston, Miami, New York, Chicago, Nashville, Atlanta, Philadelphia and Las Vegas. In fact it appears the most inconvenient location the new plane has been used to access is Bloomington, Indiana, near where we understand former Chairman Ed Hutton and current director Sandra Laney both keep personal residences.

In Chemed's March 16, 2009 letter rejecting MMI's demand in its February 12, 2009 letter for a tax-free spin-off of one of the company's two subsidiaries, CEO Kevin McNamara cited the "current market environment" as the primary reason Chemed would not proceed with a split-up and implied that Chemed would revisit the issue at the proper time. We can think of no reason stockholders could possibly trust the timing of a management and board who chose to upgrade its private jet fleet at stockholder expense in the midst of a 100-year storm in the global economy. MMI's decision to nominate its highly qualified slate of independent director candidates was due to our concerns about such decision-making.

We recognize that as a long-term board member you participated in the decision to purchase this aircraft, yet we nonetheless are hopeful that Chemed will begin the process of addressing its entrenched culture of corporate largesse in advance of the 2009 annual meeting.

                                Sincerely,


                                Clay Lifflander

CERTAIN INFORMATION CONCERNING THE PARTICIPANTS

MMI Investments, L.P., a Delaware limited partnership ("MMI Investments"), together with the other participants named below, has made a preliminary filing with the Securities and Exchange Commission ("SEC") of a proxy statement (the "Proxy Statement") and an accompanying proxy card to be used to solicit votes in connection with the solicitation of proxies in support its director nominees at the 2009 Annual Meeting of Stockholders of Chemed Corporation (the "Company").

MMI INVESTMENTS ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. IN ADDITION, THE PARTICIPANTS IN THE PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WHEN AVAILABLE WITHOUT CHARGE UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR, MACKENZIE PARTNERS, INC. BY CALLING (800) 322-2885. ANY SUCH PROXY MATERIALS WILL ALSO BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV.

The participants in the proxy solicitation are MMI Investments, MCM Capital Management, LLC ("MCM"), which is the general partner of MMI Investments, John S. Dyson, who is Chairman and a voting member of MCM, Clay B. Lifflander, who is President and a voting member of MCM, Scott J. Cromie, James Foy, Peter A, Michel and Carroll R. Wetzel, Jr. (the "Group"). As of April 1, 2009, MMI Investments beneficially owned 800,000 shares of common stock, $1 par value per share (the "Common Stock"), of the Company, which shares represent approximately 3.6% of the outstanding Common Stock, and Mr. Cromie beneficially owned two shares of Common Stock. Except for the shares owned by MMI Investments and Mr. Cromie, which each member of the Group may be deemed to beneficially own under SEC rules, none of the other members of the Group beneficially owns any Common Stock of the Company. Additional information concerning MMI Investments and the other members of the Group will be included in the Proxy Statement.


'/>"/>
SOURCE MMI Investments, L.P.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MMI Investments, L.P. Calls on Chemed Board to Pursue a Tax-Free Spin-Off of One of Its Two Businesses
2. Psychemedics Corporation Announces Third Quarter Results
3. Raymond J. Ruddy Joins Psychemedics Corporation As Top Financial Officer
4. Psychemedics Corporation Announces Second Quarter Results
5. Psychemedics Corporation Announces First Quarter Results
6. Psychemedics Corporation Announces Year End Results Record Annual and Quarterly Revenue
7. Jennifer Chmieleski Joins Psychemedics Corporation as Top Financial Officer
8. Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book
9. AMERIGROUP Corporation to Discuss First Quarter Earnings on May 1
10. Waters Corporation Announces the Purchase of UPLC/MS Systems by the National Cancer Institute for Advanced Metabolomics Research
11. Chem Rx Corporation in Technical Violation of Three Financial Debt Covenants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , ... May 02, 2016 , ... ... & Analytics EVP and GM Jim Callandrillo and Duane Reed, VP of ... 55th Annual Pharmaceutical Business Intelligence and Research Group (PBIRG) General Meeting from ...
(Date:5/2/2016)... ... May 02, 2016 , ... Atlantic Information Services, Inc. ... Part B Payment Model Could Transform the Pharma Landscape .” CMS recently proposed a ... its spend on provider-administered drugs while preserving care provided to beneficiaries. The webinar will ...
(Date:5/2/2016)... ... May 02, 2016 , ... For many artists, the act of blending paint ... it into a science. , Using the new, highly precise METTLER TOLEDO ML204T ... add depth and meaning to his works. What’s more, it has allowed him to ...
(Date:5/2/2016)... ... May 02, 2016 , ... The debilitating disease of arthritis ... With no cure, most patients must deal with prescription costs to treat arthritis over ... up to 75% savings at the pharmacy on many common prescriptions. , Arthritis , ...
(Date:5/2/2016)... ... May 02, 2016 , ... Summit ... announced the opening of Twin Lakes Recovery Center. Located east of Atlanta ... the state. The residential facility is set on 34 acres of beautiful, ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Research and Markets has announced the addition ... report to their offering.      (Logo: ... plastic surgery products market is expected to grow at ... ,The growing adoption of laser in aesthetics is another ... Lasers are used to treat a broad range of ...
(Date:4/28/2016)... , April 28, 2016 ... insights on healthcare, announced today that it has been ... Cool Vendor in Life Sciences, 2016, ... 2016.  The report focuses on life-science- oriented analytics, algorithms ... from patients and doctors, confirm medication ingestion, and analyze ...
(Date:4/28/2016)... --  Acsis , a leading provider of supply chain ... and advisory firm IDC has named it a " ... Track and Trace Software 2016 Vendor Assessment (doc # ... the capabilities and business strategies of 10 vendors in ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
Breaking Medicine Technology: